Interactions

Active ingredient Pseudoephedrine interacts in the following cases:

Monoamine oxidase inhibitors

Pseudoephedrine should not be given to patients being treated with monoamine oxidase inhibitors or within 14 days of stopping such treatment.

Tricyclic antidepressants

Pseudoephedrine may enhance the effects of anticholinergic drugs such as tricyclic antidepressants.

Ergot alkaloids

Pseudoephedrine may increase the vasoconstrictor effects of ergot alkaloids.

Lactation

The safety of decongestant tablets during lactation has not been established. The amounts of pseudoephedrine secreted into breast milk are considered to be too small to be harmful.

Pregnancy

The safety of decongestant tablets during pregnancy has not been established but in view of a possible association of foetal abnormalities with first trimester exposure to pseudoephedrine, the use of the product during pregnancy should be avoided.

Digitalis

Pseudoephedrine may increase the possibility of arrhythmias in digitalised patients.

Pregnancy

The safety of decongestant tablets during pregnancy has not been established but in view of a possible association of foetal abnormalities with first trimester exposure to pseudoephedrine, the use of the product during pregnancy should be avoided.

Nursing Mothers

The safety of decongestant tablets during lactation has not been established. The amounts of pseudoephedrine secreted into breast milk are considered to be too small to be harmful.

Effects on Ability to Drive and Use Machines

No adverse effects known.